Teligent competitorsClear all
Teligent's top competitors include Otonomy, Shire and Pharnext.
| Save Comparison |  Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. |  Pharnext Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases. | ||
Founding Date | Founding Date 1977 | Founding Date 2008 | Founding Date 1986 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Vineland, US HQ Mississauga, CA Tallinn, EE Woodbridge Township, US | Locations San Diego, US HQ | Locations Issy-les-Moulineaux, FR HQ | |
Employees | Employees 1893% increase | Employees 498% decrease | Employees 23,044 | Employees 4319% increase |
Valuation ($) | Valuation ($) 29.5 m | Valuation ($) 73.6 m | Valuation ($) 54.8 b | Valuation ($) 123.1 m |
Twitter followers | Twitter followers 94 | Twitter followers 233 | Twitter followers 7.7 k | Twitter followers 1.6 k |
Alexa Website Rank | Alexa Website Rank 1321607 | Alexa Website Rank 318925 | Alexa Website Rank 333836 | Alexa Website Rank 1335066 |
Financial | ||||
Revenue (est.) | Revenue (est.) $158.3m (FY, 2018) | Revenue (est.) $745k (FY, 2018) | Revenue (est.) £43m (FY, 2018) | Revenue (est.) N/A |
Cost of goods | Cost of goods $43.5m (FY, 2018) | Cost of goods $946k (FY, 2018) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $114.8m (FY, 2018) | Gross profit ($201k) (FY, 2018) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($36.3m) (FY, 2018) | Net income ($50.4m) (FY, 2018) | Net income £3.4m (FY, 2018) | Net income N/A |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products 7 (FY, 2017) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 2 (FY, 2016) | Phase II Trials Products 10 (FY, 2017) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products 15 (FY, 2017) | Phase III Trials Products N/A |
Preclinical Phase Products | Preclinical Phase Products N/A | Preclinical Phase Products 1 (FY, 2016) | Preclinical Phase Products 35 (FY, 2017) | Preclinical Phase Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 16.1m | Total funding raised $ 153.4m | Total funding raised N/A | Total funding raised $ 10.6m |
For sources of this data, please see the company profile
View company profiles
Otonomy
HQ
San Diego, US
Employees
49↓ 8% decrease
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
View companyPharnext
HQ
Issy-les-Moulineaux, FR
Employees
43↑ 19% increase
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
View company